Escaping antiangiogenic therapy: Strategies employed by cancer cells

Mauricio P. Pinto, Paula Sotomayor, Gonzalo Carrasco-Avino, Alejandro H. Corvalan, Gareth I. Owen

Resultado de la investigación: Contribución a la publicaciónReview article

  • 12 Citas

Resumen

Tumor angiogenesis is widely recognized as one of the "hallmarks of cancer". Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and clinical cancer research. While antiangiogenic drugs are now incorporated into standard clinical practice, as with all cancer therapies, tumors can eventually become resistant by employing a variety of strategies to receive nutrients and oxygen in the event of therapeutic assault. Herein, we concentrate and review in detail three of the principal mechanisms of antiangiogenic therapy escape: (1) upregulation of compensatory/alternative pathways for angiogenesis; (2) vasculogenic mimicry; and (3) vessel co-option. We suggest that an understanding of how a cancer cell adapts to antiangiogenic therapy may also parallel the mechanisms employed in the bourgeoning tumor and isolated metastatic cells delivering responsible for residual disease. Finally, we speculate on strategies to adapt antiangiogenic therapy for future clinical uses.

IdiomaEnglish
Número de artículo1489
PublicaciónInternational Journal of Molecular Sciences
Volumen17
Número de edición9
DOI
EstadoPublished - 6 sep 2016

Huella dactilar

Tumors
therapy
cancer
Cells
angiogenesis
tumors
Neoplasms
Angiogenesis Inhibitors
Nutrients
nutrients
Therapeutics
inhibitors
Oxygen
escape
vessels
drugs
Testing
Pharmaceutical Preparations
oxygen
cells

Keywords

    ASJC Scopus subject areas

    • Catalysis
    • Molecular Biology
    • Spectroscopy
    • Computer Science Applications
    • Physical and Theoretical Chemistry
    • Organic Chemistry
    • Inorganic Chemistry

    Citar esto

    Pinto, Mauricio P. ; Sotomayor, Paula ; Carrasco-Avino, Gonzalo ; Corvalan, Alejandro H. ; Owen, Gareth I./ Escaping antiangiogenic therapy : Strategies employed by cancer cells. En: International Journal of Molecular Sciences. 2016 ; Vol. 17, N.º 9.
    @article{2b01303887634f65ac27238330b8a86e,
    title = "Escaping antiangiogenic therapy: Strategies employed by cancer cells",
    abstract = "Tumor angiogenesis is widely recognized as one of the {"}hallmarks of cancer{"}. Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and clinical cancer research. While antiangiogenic drugs are now incorporated into standard clinical practice, as with all cancer therapies, tumors can eventually become resistant by employing a variety of strategies to receive nutrients and oxygen in the event of therapeutic assault. Herein, we concentrate and review in detail three of the principal mechanisms of antiangiogenic therapy escape: (1) upregulation of compensatory/alternative pathways for angiogenesis; (2) vasculogenic mimicry; and (3) vessel co-option. We suggest that an understanding of how a cancer cell adapts to antiangiogenic therapy may also parallel the mechanisms employed in the bourgeoning tumor and isolated metastatic cells delivering responsible for residual disease. Finally, we speculate on strategies to adapt antiangiogenic therapy for future clinical uses.",
    keywords = "Cancer dormancy, Residual disease, Vascular co-option, Vasculogenic mimicry",
    author = "Pinto, {Mauricio P.} and Paula Sotomayor and Gonzalo Carrasco-Avino and Corvalan, {Alejandro H.} and Owen, {Gareth I.}",
    year = "2016",
    month = "9",
    day = "6",
    doi = "10.3390/ijms17091489",
    language = "English",
    volume = "17",
    journal = "International Journal of Molecular Sciences",
    issn = "1661-6596",
    publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
    number = "9",

    }

    Escaping antiangiogenic therapy : Strategies employed by cancer cells. / Pinto, Mauricio P.; Sotomayor, Paula; Carrasco-Avino, Gonzalo; Corvalan, Alejandro H.; Owen, Gareth I.

    En: International Journal of Molecular Sciences, Vol. 17, N.º 9, 1489, 06.09.2016.

    Resultado de la investigación: Contribución a la publicaciónReview article

    TY - JOUR

    T1 - Escaping antiangiogenic therapy

    T2 - International Journal of Molecular Sciences

    AU - Pinto,Mauricio P.

    AU - Sotomayor,Paula

    AU - Carrasco-Avino,Gonzalo

    AU - Corvalan,Alejandro H.

    AU - Owen,Gareth I.

    PY - 2016/9/6

    Y1 - 2016/9/6

    N2 - Tumor angiogenesis is widely recognized as one of the "hallmarks of cancer". Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and clinical cancer research. While antiangiogenic drugs are now incorporated into standard clinical practice, as with all cancer therapies, tumors can eventually become resistant by employing a variety of strategies to receive nutrients and oxygen in the event of therapeutic assault. Herein, we concentrate and review in detail three of the principal mechanisms of antiangiogenic therapy escape: (1) upregulation of compensatory/alternative pathways for angiogenesis; (2) vasculogenic mimicry; and (3) vessel co-option. We suggest that an understanding of how a cancer cell adapts to antiangiogenic therapy may also parallel the mechanisms employed in the bourgeoning tumor and isolated metastatic cells delivering responsible for residual disease. Finally, we speculate on strategies to adapt antiangiogenic therapy for future clinical uses.

    AB - Tumor angiogenesis is widely recognized as one of the "hallmarks of cancer". Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and clinical cancer research. While antiangiogenic drugs are now incorporated into standard clinical practice, as with all cancer therapies, tumors can eventually become resistant by employing a variety of strategies to receive nutrients and oxygen in the event of therapeutic assault. Herein, we concentrate and review in detail three of the principal mechanisms of antiangiogenic therapy escape: (1) upregulation of compensatory/alternative pathways for angiogenesis; (2) vasculogenic mimicry; and (3) vessel co-option. We suggest that an understanding of how a cancer cell adapts to antiangiogenic therapy may also parallel the mechanisms employed in the bourgeoning tumor and isolated metastatic cells delivering responsible for residual disease. Finally, we speculate on strategies to adapt antiangiogenic therapy for future clinical uses.

    KW - Cancer dormancy

    KW - Residual disease

    KW - Vascular co-option

    KW - Vasculogenic mimicry

    UR - http://www.scopus.com/inward/record.url?scp=84985961179&partnerID=8YFLogxK

    U2 - 10.3390/ijms17091489

    DO - 10.3390/ijms17091489

    M3 - Review article

    VL - 17

    JO - International Journal of Molecular Sciences

    JF - International Journal of Molecular Sciences

    SN - 1661-6596

    IS - 9

    M1 - 1489

    ER -

    Pinto MP, Sotomayor P, Carrasco-Avino G, Corvalan AH, Owen GI. Escaping antiangiogenic therapy: Strategies employed by cancer cells. International Journal of Molecular Sciences. 2016 sep 6;17(9). 1489. Disponible desde, DOI: 10.3390/ijms17091489